ELAHERE is indicated to treat adults with folate receptor-alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who had previously received up to three systemic therapies.
It is currently authorised under accelerated approval, based on the durability of response and the tumour response rate.
ImmunoGen will supply the product for development as well as for commercial use in Japan. Takeda will be responsible for all regulatory filings and obligations.
ImmunoGen will receive a one-time upfront payment, and a potential additional payment following the conversion of the US Food and Drug Administration’s accelerated approval of ELAHERE to full approval, totaling $34 million.
ImmunoGen will also be eligible for additional payments and double-digit royalties on future ELAHERE net sales in Japan, on condition that Takeda achieves prespecified regulatory and commercial milestones.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Takeda global oncology unit president Teresa Bitetti stated: “The data from the Phase III MIRASOL study demonstrate the potential for ELAHERE to become the new standard of care for this devastating disease, and we are confident this collaboration with ImmunoGen will bring significant value to patients in Japan.
“This investment is reflective of Takeda’s commitment to partnering with organisations that share our passion for developing new medicines for cancers with limited or ineffective treatment options, and brings us one step closer to achieving our aspiration to cure cancer.”
ELAHERE is an antibody-drug conjugate that includes a folate receptor alpha-binding antibody and a cleavable linker.
It also comprises the maytansinoid payload DM4, a potent tubulin inhibitor for killing the targeted cancer cells.
Note: The fifth paragraph was updated to reflect the correct payment structure for this deal, on 29 August.